Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus

BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Med Res
Egile Nagusiak: Chiba, Yukari, Yamakawa, Tadashi, Tsuchiya, Hirohisa, Oba, Mari, Suzuki, Daisuke, Danno, Hirosuke, Takatsuka, Yoji, Shigematsu, Hiroshi, Kaneshiro, Mizuki, Terauchi, Yasuo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elmer Press 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6031245/
https://ncbi.nlm.nih.gov/pubmed/29977423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3464w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak